CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 103 enrolled
Drug / intervention
CLCdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02679287
NCT02679287N/ACompleted
CompareCT.gov

Project Nightlight: Efficacy and System Acceptance of Dinner/Night vs. 24hr Closed Loop Control

University of Virginia·interventional·Posted Feb 10, 2016·Updated Jun 9, 2020

In Brief

A clinical study evaluating CLC for Diabetes Mellitus, Type 1. Completed, enrolled 103 participants across 1 site.

Detailed Summary

The purpose of this study is to use an investigational type of technology called Closed-Loop Control (CLC) Medical Platform System to help control blood sugar in people with type 1 diabetes mellitus in a home setting.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 1
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Roche Diagnostic Ltd., TypeZero Technologies, LLC, Tandem Diabetes Care, Inc., DexCom, Inc.

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 10, 2016
Enrollment StartFeb 1, 2016
Primary CompletionApr 1, 2019
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 10.4 years ago

Interventions

CLCdevice

The CLC will be deployed with different functionalities at different stages of the trial, resulting in variation in what the subject will be responsible for and what the system will drive.